Naproxcinod 750 mg non-inferior to naproxen in the reduction of knee OA symptoms
Naproxcinod 750 mg non-inferior to naproxen in the reduction of knee OA symptoms
Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: A 13-week prospective, randomized, multicenter study
Osteoarthritis Cartilage. 2010 May;18(5):629-39. Epub 2010 Feb 16Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
918 patients (>=40 yr) with osteoarthritis (OA) of the knee and managed with oral NSAIDs or acetaminophen, were randomized to 4 groups of either naproxcinod (750 or 375 mg), naproxen (50 mg) or a placebo. At study conclusion (i.e. 13 weeks), naproxcinod was found to be well-tolerated and did not significantly elevate blood pressure more than naproxen. Naproxcinod's clinical efficacy is statistical...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.